Elena PÉREZ CEBALLOS

Peñalver FJ, Delgado J, Loscertales J, Sastre JL, Peña A, Olave MT, Osorio S, de la Fuente A, Salar A, Grande C, Pérez Ceballos E, Debén G, Echeveste A, Casado F, de la Rubia J, Lahuerta JJ, Mateos MV. Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma. Eur J Haematol. 2016 May;96(5):532-40. doi: 10.1111/ejh.12633. Epub 2015 Aug 9. PubMed PMID: 26179864.

AÑO: 2016; IF: 2.653

26179864

Martínez C, Díaz-López A, Rodriguez-Calvillo M, García-Sanz R, Terol MJ, Pérez-Ceballos E, Jiménez MJ, Cantalapiedra A, Domingo-Domenech E, Rodriguez MJ, Sampol A, Espeso M, López FJ, Briones J, García JF, Sureda A; Hodgkin Lymphoma Subcommittee of Spanish Group of Lymphoma Bone Marrow Transplantation(GELTAMO). Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy. Br J Haematol. 2016 Sep;174(6):859-67. doi: 10.1111/bjh.14133. Epub 2016 May 17. PubMed PMID: 27185197.

AÑO: 2016; IF: 5.67

27185197

Chen-Liang TH, Martin-Santos T, Jerez A, Senent L, Orero MT, Remigia MJ, Muiña B, Romera M, Fernandez-Muñoz H, Raya JM, Fernandez-Gonzalez M, Lancharro A, Villegas C, Carlos Herrera J, Frutos L, Luis Navarro J, Uña J, Igua C, Sanchez-Vaño R, Cozar Mdel P, Contreras J, Sanchez-Blanco JJ, Perez-Ceballos E, Ortuño FJ. The role of bone marrow biopsy and FDG-PET/CT in identifying bone marrow infiltration in the initial diagnosis of high grade non-Hodgkin B-cell lymphoma and Hodgkin lymphoma. Accuracy in a multicenter series of 372 patients. Am J Hematol. 2015 Aug;90(8):686-90. doi: 10.1002/ajh.24044. Erratum in: Am J Hematol. 2016 May;91(5):E300. PubMed PMID: 25925613.

AÑO: 2015; IF: 5.0

25925613

Heredia-Galvez B, Ruiz-Cosano J, Torres-Moreno D, Español I, Morales-Lara MJ, Pérez-Ceballos E, González-Conejero R, Gutiérrez-Cívicos R, Vicente V, Pérez-Guillermo M, Conesa-Zamora P. Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas. Ann Hematol. 2014 Feb;93(2):243-7. doi: 10.1007/s00277-013-1864-4. PubMed PMID: 23959437.

AÑO: 2014; IF: 2.634

23959437

Pardal E, Coronado M, Martín A, Grande C, Marín-Niebla A, Panizo C, Bello JL, Conde E, Hernández MT, Arranz R, Bargay J, González-Barca E, Pérez-Ceballos E, Montes-Moreno S, Caballero MD. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. Br J Haematol. 2014 Nov;167(3):327-36. doi: 10.1111/bjh.13036. PubMed PMID: 25066542.

AÑO: 2014; IF: 4.971

25066542